Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 162 vs intravenous bisphosphonates in advanced cancer with bone disease
2004-000511-25Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in bone metastases and multiple myeloma (MM) (3 arms), sponsored by Amgen. Primary endpoint: Proportion of subjects with uNTx < 50 nM BCE/mM creatinine at week 13. Started Feb 2009; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasesmultiple myeloma (MM)
Beyond the preview
Go deeper on 2004-000511-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000511-25.